UK MHRA Awards Bluebird’s LentiGlobin An Innovation Passport
Bluebird Is Calling On Companies To Share Experiences Of ILAP
Companies that are in earlier stages of the drug development process will benefit most from the UK regulator's new pathway for innovative medicines.
You may also be interested in...
The UK has the potential to fulfill its ambition of being a global superpower in life sciences, but it must not get lost in an echo chamber, says a senior MSD executive.
The cancer drug is also to undergo an accelerated assessment by the European Medicines Agency.
The European Medicines Agency is reviewing the safety of bluebird bio’s beta thalassaemia gene therapy, which is so far only approved in the EU and has only been used in one patient outside the context of clinical studies.